Voyager Therapeutics
VYGR
132 hedge funds and large institutions have $196M invested in Voyager Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 18 closing their positions.
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
19% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 37
3% more funds holding
Funds holding: 128 → 132 (+4)
5% less capital invested
Capital invested by funds: $206M → $196M (-$9.78M)
1.09% less ownership
Funds ownership: 64.44% → 63.35% (-1.1%)
42% less call options, than puts
Call options by funds: $273K | Put options by funds: $474K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$4.77M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.8M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.78M |
| 4 |
AC
Armistice Capital
New York
|
+$1.26M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3.31M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.23M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.57M |
| 4 |
Renaissance Technologies
New York
|
-$895K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$870K |
VYGR Hedge Fund Activity: Q4 2024 in Review
132 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2024, worth a combined $196M — down 4.8% from $206M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VYGR positions and 18 closed out — a net gain of 7 holders — while 44 added to existing stakes and 37 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $4.77M. The largest seller was Bank of America, cutting an estimated $3.31M.
- 132 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2024, up from 128 in Q3 2024.
- Funds reported $196M of Voyager Therapeutics stock for Q4 2024, down 4.8% quarter-over-quarter.
- 25 funds opened new Voyager Therapeutics positions in Q4 2024 and 18 closed out, a net change of +7 holders.
- The largest Voyager Therapeutics buyer in Q4 2024 was Vestal Point Capital, an estimated $4.77M added.
- The largest Voyager Therapeutics seller in Q4 2024 was Bank of America, an estimated $3.31M sold.
Based on aggregated 13F filings for Q4 2024.